A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This is a 24 week study comparing the efficacy of four dose levels of INT131 besylate with
pioglitazone HCl in patients with type 2 diabetes. Eligible patients will be men and women
(of non-childbearing potential or using dual barrier methods of contraception) between 30 and
75 years of age who are minimally responsive to treatment with sulfonylurea monotherapy or
sulfonylurea plus metformin combination therapy.